Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes

Histopathology

Volumn 61, Issue 4, 2012, Pages 629-643

  Di Palma, Silvana ^a,b   Simpson, Roderick H W ^c   Marchió, Caterina ^d   Skálová, Alena ^e   Ungari, Marco ^f   Sandison, Ann ^g   Whitaker, Stephen ^a   Parry, Suzanne ^d   Reis Filho, Jorge S ^d  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

^c ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e CHARLES UNIVERSITY   (Czech Republic)

^f SPEDALI CIVILI   (Italy)

^g CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Androgen receptor; Basal cytokeratins; Basal like phenotype; HER2; Molecular subtypes; Salivary ductcarcinoma

Indexed keywords

ANDROGEN RECEPTOR; ANTIBODY; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MOLECULAR MARKER; PROGESTERONE RECEPTOR; TUMOR MARKER; AR PROTEIN, HUMAN; ERBB2 PROTEIN, HUMAN; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; BASAL LIKE PHENOTYPE; BREAST CARCINOMA; CANCER CLASSIFICATION; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; SALIVARY GLAND DUCT CARCINOMA; SCORING SYSTEM; BIOSYNTHESIS; CARCINOMA; CARCINOMA IN SITU; CLASSIFICATION; DNA MICROARRAY; GENETICS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; SALIVARY GLAND DUCT; SALIVARY GLAND TUMOR; TISSUE MICROARRAY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA; CARCINOMA IN SITU; CARCINOMA, DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; SALIVARY DUCTS; SALIVARY GLAND NEOPLASMS; TISSUE ARRAY ANALYSIS; TRANSCRIPTOME;

EID: 84871918990     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04252.x     Document Type: Article

References (74)

1. Kleinsasser O, Klein HH, Huübner G. Speichelgangcarcinom: ein den milchgangcarcinomen der bruü stdruse analoge gruppe von speicheldruüsentumoren (Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma). Archiv. Klin. Exp. Ohren Nasen Kehlkopfheilkunde 1968; 192; 100-115.
2. Seifert G. World Health Organization international histological classification of tumours: histological typing of salivary gland tumours. Berlin: Springer-Verlag, 1991.
3. Barnes L, Eveson JW, Reichart P, Sidransky D eds. Tumours of the salivary glands. World Health Organization classification of tumours pathology and genetics of head and neck tumours. Lyon: IARC Press, 2005; 209-281.
4. Simpson RHW, Di Palma S. Selected recent advances in the pathology of salivary neoplasms. Diagn. Histopathol. 2010; 16; 276-286.
5. van Heerden WF, Raubenheimer EJ, Swart TJ, Boy SC. Intraoral salivary duct carcinoma: a report of 5 cases. J. Oral Maxillofac. Surg. 2003; 61; 126-131.
6. Simpson RH, Pereira EM, Ribeiro AC, Abdulkadir A, Reis-Filho JS. Polymorphous low-grade adenocarcinoma of the salivary glands with transformation to high-grade carcinoma. Histopathology 2002; 41; 250-259.
7. Ellis GL, Auclair PL. Salivary duct carcinoma. AFIP atlas of tumor pathology, 4th series, fascicle 9. Tumors of the salivary glands. American Registry of Pathology. Washington, DC: ARP Publications, 2008; 322-332.
8. Lewis JE, McKinney BC, Weiland LH, Ferreiro JA, Olsen KD. Salivary duct carcinoma. Clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996; 77; 223-230.
9. Afzelius LE, Cameron WR, Svensson C. Salivary duct carcinoma - a clinicopathologic study of 12 cases. Head Neck Surg. 1987; 9; 151-156.
10. Brandwein MS, Jagirdar J, Patil J, Biller H, Kaneko M. Salivary duct carcinoma (cribriform salivary carcinoma of excretory ducts). A clinicopathologic and immunohistochemical study of 12 cases. Cancer 1990; 65; 2307-2314.
11. Garland TA, Innes DJ Jr, Fechner RE. Salivary duct carcinoma: an analysis of four cases with review of literature. Am. J. Clin. Pathol. 1984; 81; 436-441.
12. Guzzo M, Di Palma S, Grandi C, Molinari R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 1997; 19; 126-133.
13. Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A et al. Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J. Craniomaxillofac. Surg. 1997; 25; 328-334.
14. Simpson RH, Clarke TJ, Sarsfield PT, Babajews AV. Salivary duct adenocarcinoma. Histopathology 1991; 18; 229-235.
15. de Araujo VC, Kowalski LP, Soares F et al. Salivary duct carcinoma: cytokeratin 14 as a marker of in-situ intraductal growth. Histopathology 2002; 41; 244-249.
16. Di Palma S, Simpson RHW, Ska'lova' A, Leivo I. Major and minor salivary glands. In Cardesa A, Slootweg PJ eds. Pathology of the head and neck. Berlin: Springer, 2006; 131-170.
17. Kapadia SB, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod. Pathol. 1998; 11; 1033-1038.
18. Di Palma S, Skalova A, Vanieek T et al. Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry. Histopathology 2005; 46; 144-152.
19. Jaehne M, Jakel KT, Roser K, Ussmuller J, Loning T. About the prognostic value of Her-2 gene-amplification and cell-proliferation in salivary duct carcinoma of the major salivary glands - a pilot-study. Laryngorhinootologie 2001; 80; 525-529.
20. Johnson CJ, Barry MB, Vasef MA, Deyoung BR. Her-2/neu expression in salivary duct carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Appl. Immunohistochem. Mol. Morphol. 2008; 16; 54-58.
21. Skalova A, Starek I, Vanecek T et al. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohistochemistry. Histopathology 2003; 42; 348-356.
22. Sugano S, Mukai K, Tsuda H et al. Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 1992; 102; 923-927.
23. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
24. Williams MD, Roberts D, Blumenschein GR Jr et al. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am. J. Surg. Pathol. 2007; 31; 1645-1652.
25. Williams MD, Roberts DB, Kies MS et al. Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance. Clin. Cancer Res. 2010; 16; 2266-2274.
26. Barnes L, Rao U, Contis L et al. Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg. Oral Med. Oral Pathol. 1994; 78; 74-80.
27. Delgado R, Vuitch F, Albores-Saavedra J. Salivary duct carcinoma. Cancer 1993; 72; 1503-1512.
28. Nasser SM, Faquin WC, Dayal Y. Expression of androgen, estrogen, and progesterone receptors in salivary gland tumors. Frequent expression of androgen receptor in a subset of malignant salivary gland tumors. Am. J. Clin. Pathol. 2003; 119; 801-806.
29. Wick MR, Ockner DM, Mills SE, Ritter JH, Swanson PE. Homologous carcinomas of the breasts, skin, and salivary glands. A histologic and immunohistochemical comparison of ductal mammary carcinoma, ductal sweat gland carcinoma, and salivary duct carcinoma. Am. J. Clin. Pathol. 1998; 109; 75-84.
30. Fan CY, Wang J, Barnes EL. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma: an immunohistochemical analysis of 13 cases and review of the literature. Am. J. Surg. Pathol. 2000; 24; 579-586.
31. Isola JJ. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J. Pathol. 1993; 170; 31-35.
32. Moinfar F, Okcu M, Tsybrovskyy O et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003; 98; 703-711.
33. Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 2001; 93; 344-350.
34. Weigelt B, Baehner FL, Reis-Filho JS. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 2010; 220; 263-280.
35. Weigelt B, Pusztai L, Ashworth A, Reis-Filho JS. Challenges translating breast cancer gene signatures into the clinic. Nat. Rev. Clin. Oncol. 2011; 9; 58-64.
36. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406; 747-752.
37. Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005; 24; 4660-4671.
38. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25; 3994-4008.
39. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011; 121; 2750-2767.
40. Hu Z, Fan C, Oh DS et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7; 96.
41. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 2001; 98; 10869-10874.
42. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 2004; 10; 5367-5374.
43. Brandwein-Gensler MS, Ska'lova' A, Nagao T. Salivary duct carcinoma. In Barnes L, Eveson JW, Reichart P, Sidransky D eds. World Health Organization classification of tumours pathology and genetics of head and neck tumours. Lyon: IARC Press, 2005; 236-237.
44. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19; 403-410.
45. Tan DS, Marchio C, Jones RL et al. Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline- treated patients. Breast Cancer Res. Treat. 2008; 111; 27-44.
46. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 1999; 17; 1474-1481.
47. Reis-Filho JS, Milanezi F, Steele D et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006; 49; 10-21.
48. Rakha EA, El-Sayed ME, Green AR et al. Breast carcinoma with basal differentiation: a proposal for pathology definition based on basal cytokeratin expression. Histopathology 2007; 50; 434-438.
49. Simpson RH, Desai S, Di Palma S. Salivary duct carcinoma in situ of the parotid gland. Histopathology 2008; 53; 416-425.
50. Weigelt B, Mackay A, A'Hern R et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010; 11; 339-349.
51. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J. Clin. Oncol. 2008; 26; 2568-2581.
52. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52; 108-118.
53. Hungermann D, Roeser K, Buerger H et al. Salivary duct carcinoma. Pathologe 2005; 26; 353-358.
54. Fulford LG, Easton DF, Reis-Filho JS et al. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006; 49; 22-34.
55. Livasy CA, Karaca G, Nanda R et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod. Pathol. 2006; 19; 264-271.
56. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res. Treat. 2009; 117; 273-280.
57. Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Future Oncol. 2008; 4; 15-21.
58. Reid AH, Attard G, Danila DC et al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 2010; 28; 1489-1495.
59. Laurie SA, Licitra L. Systemic therapy in the palliative management of advanced salivary gland cancers. J. Clin. Oncol. 2006; 24; 2673-2678.
60. Locati LD, Bossi B, Rinaldi GR et al. Anti-androgen therapy in recurrent and/or metastatic salivary glands carcinoma (RSGC). Ann. Oncol. 2006; 16; iii38.
61. Locati LD, Quattrone P, Bossi P et al. A complete remission with androgen-deprivation therapy in a recurrent androgen receptorexpressing adenocarcinoma of the parotid gland. Ann. Oncol. 2003; 14; 1327-1328.
62. Bryan BB, Schnitt SJ, Collins LC. Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod. Pathol. 2006; 19; 617-621.
63. Dabbs DJ, Chivukula M, Carter G, Bhargava R. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod. Pathol. 2006; 19; 1506-1511.
64. Livasy CA, Perou CM, Karaca G et al. Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum. Pathol. 2007; 38; 197-204.
65. Latta EK, Tjan S, Parkes RK, O'Malley FP. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod. Pathol. 2002; 15; 1318-1325.
66. Haddad R, Colevas AD, Krane JF et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol. 2003; 39; 724-727.
67. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J. Clin. Oncol. 2010; 28; 1145-1153.
68. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009; 361; 123-134.
69. O'Shaughnessy J, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 2010; 364; 205-214.
70. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376; 235-244.
71. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N. Engl. J. Med. 2010; 363; 1938-1948.
72. Delgado R, Klimstra D, Albores-Saavedra J. Low grade salivary duct carcinoma. A distinctive variant with a low grade histology and a predominant intraductal growth pattern. Cancer 1996; 78; 958-967.
73. Brandwein-Gensler M, Hille J, Wang BY et al. Low-grade salivary duct carcinoma: description of 16 cases. Am. J. Surg. Pathol. 2004; 28; 1040-1044.
74. Weinreb I, Tabanda-Lichauco R, Van der Kwast T, Perez- Ordonez B. Low-grade intraductal carcinoma of salivary gland: report of 3 cases with marked apocrine differentiation. Am. J. Surg. Pathol. 2006; 30; 1014-1021.